Erratum: Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists (American Journal of Health-System Pharmacy (2020) DOI: 10.1093/ajhp/zxaa413)

Medicine and Dentistry

• Patient 70%
• Adjustment 40%
• Inpatient 30%
• Cardiovascular System 20%
• 4 Iodo 2,5 Dimethoxyamphetamine 20%
• Patient with Type 2 Diabetes 20%
• Glucagon 20%
• Salicylate Sodium 20%
• Diseases 10%
• Follow up 10%
• Maturity Onset Diabetes of the Young 10%
• Adverse Event 10%
• Expectation 10%
• Health System 10%
• Pharmacist 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Semaglutide 100%
• Diabetes Mellitus 30%
• Receptor Agonist 20%
• 2,5-Dimethoxy-4-iodoamphetamine 20%
• Glucagon 20%
• Salicylate Sodium 20%
• Diseases 10%
• Adverse Event 10%
• Non Insulin Dependent Diabetes Mellitus 10%